» Articles » PMID: 21763736

Brain Tumor Targeting of Magnetic Nanoparticles for Potential Drug Delivery: Effect of Administration Route and Magnetic Field Topography

Overview
Specialty Pharmacology
Date 2011 Jul 19
PMID 21763736
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous studies demonstrated feasibility of magnetically-mediated retention of iron oxide nanoparticles in brain tumors after intravascular administration. The purpose of this study was to elucidate strategies for further improvement of this promising approach. In particular, we explored administration of the nanoparticles via a non-occluded carotid artery as a way to increase the passive exposure of tumor vasculature to nanoparticles for subsequent magnetic entrapment. However, aggregation of nanoparticles in the afferent vasculature interfered with tumor targeting. The magnetic setup employed in our experiments was found to generate a relatively uniform magnetic flux density over a broad range, exposing the region of the afferent vasculature to high magnetic force. To overcome this problem, the magnetic setup was modified with a 9-mm diameter cylindrical NdFeB magnet to exhibit steeper magnetic field topography. Six-fold reduction of the magnetic force at the injection site, achieved with this modification, alleviated the aggregation problem under the conditions of intact carotid blood flow. Using this setup, carotid administration was found to present 1.8-fold increase in nanoparticle accumulation in glioma compared to the intravenous route at 350mT. This increase was found to be in reasonable agreement with the theoretically estimated 1.9-fold advantage of carotid administration, R(d). The developed approach is expected to present an even greater advantage when applied to drug-loaded nanoparticles exhibiting higher values of R(d).

Citing Articles

The role of tumor model in magnetic targeting of magnetosomes and ultramagnetic liposomes.

Curcio A, Perez J, Preveral S, Fromain A, Genevois C, Michel A Sci Rep. 2023; 13(1):2278.

PMID: 36755030 PMC: 9908874. DOI: 10.1038/s41598-023-28914-4.


Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours.

Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D Nanotheranostics. 2023; 7(1):102-116.

PMID: 36593801 PMC: 9760367. DOI: 10.7150/ntno.76559.


Recent advances in mechanical force-responsive drug delivery systems.

Ma P, Lai X, Luo Z, Chen Y, Loh X, Ye E Nanoscale Adv. 2022; 4(17):3462-3478.

PMID: 36134346 PMC: 9400598. DOI: 10.1039/d2na00420h.


An Overview of Nanotechnologies for Drug Delivery to the Brain.

Ayub A, Wettig S Pharmaceutics. 2022; 14(2).

PMID: 35213957 PMC: 8875260. DOI: 10.3390/pharmaceutics14020224.


Polymeric magnetic nanoparticles: a multitargeting approach for brain tumour therapy and imaging.

Joshi B, Joshi A Drug Deliv Transl Res. 2021; 12(7):1588-1604.

PMID: 34537930 DOI: 10.1007/s13346-021-01063-9.


References
1.
Joshi S, Emala C, Pile-Spellman J . Intra-arterial drug delivery: a concise review. J Neurosurg Anesthesiol. 2007; 19(2):111-9. DOI: 10.1097/ANA.0b013e318033da41. View

2.
Lubbe A, Bergemann C, Huhnt W, Fricke T, Riess H, Brock J . Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996; 56(20):4694-701. View

3.
Delp M, Evans M, Duan C . Effects of aging on cardiac output, regional blood flow, and body composition in Fischer-344 rats. J Appl Physiol (1985). 1998; 85(5):1813-22. DOI: 10.1152/jappl.1998.85.5.1813. View

4.
Chertok B, Moffat B, David A, Yu F, Bergemann C, Ross B . Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2007; 29(4):487-96. PMC: 2761681. DOI: 10.1016/j.biomaterials.2007.08.050. View

5.
Collins J . Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984; 2(5):498-504. DOI: 10.1200/JCO.1984.2.5.498. View